Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
May 7, 2015 11:22 AM EDTNeedham & Company reiterate their Buy rating on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with the price target set $38 while awaiting the NDA filing and approval of Eteplirsen.
Needham & Company analyst, Chad Messer, commented on SRPT, saying, "A pre-NDA meeting with the FDA... More
